MET and renal carcinoma: Exosomal lncARSR could be incorporated into exosomes and transmitted to sensitive cells and then promote sunitinib resistance via competitively binding miR‐34/ miR‐449 to facilitate AXL and c‐MET expression in renal cancer cells.19